# Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients

> **NCT05474560** · PHASE4 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 90 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Hyperuricemia

## Interventions

- **DRUG:** Allopurinol (100 mg/day) plus lifestyle intervention
- **DRUG:** Febuxostat 40 mg plus lifestyle intervention
- **BEHAVIORAL:** Life style intervention

## Key facts

- **NCT ID:** NCT05474560
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-01-28
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05474560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05474560, "Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05474560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*